Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.35 (
matrix metalloproteinase 9
)
2,207
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The current study aims to evaluate for the first time the inhibitory roles of
miR-205
in the pathogenesis of anaplastic thyroid carcinoma. In addition, we investigated the mechanisms by which miR-205 regulates angiogenesis and epithelial-to-mesenchymal transition (EMT) in cancer. Two anaplastic thyroid carcinoma cell lines were transfected with the expression vector pCMV-
MIR
-205
Selected markers of angiogenesis and EMT including vascular endothelial growth factor A (
VEGF
-A
) and zinc finger E-box-binding homeobox 1 (
ZEB1
) were investigated by Western blot. The interaction of
miR-205
expression with EMT and angiogenesis were also investigated by assessment of matrix metalloproteinases 2 and 9 (MMP2 and
MMP 9
), SNAI1 (Snai1 family zinc finger 1), vimentin, E-cadherin and N-cadherin. The function of
miR-205
was further tested with VEGF enzyme-linked immunosorbent assay (ELISA), wound healing, invasion and tube formation assays. Using an animal model, we studied the association of
miR-205
with angiogenesis, proliferation and invasion. The following results were obtained. Permanent overexpression of
miR-205
significantly suppressed angiogenesis and EMT by simultaneously targeting
VEGF-A
,
ZEB1
and downstream products. Ectopic expression of
miR-205
in cancer cells led to decreased migration, invasion and tube formation of endothelial cells. In addition, inhibition of tumour growth, vascularisation and invasion were noted in the mouse tumour xenografts. Our findings provide insights into simultaneous regulatory role of
miR-205
in the pathogenesis of anaplastic thyroid carcinoma by suppressing both angiogenesis and EMT. This may open avenues to exploit
miR-205
as an alternative cancer therapeutic strategy in the future.
...
PMID:
miR-205
targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. 2931 80
